Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
Condition: Metastatic Breast Cancer Intervention: Drug: Patients who received Palbociclib as first line therapy in MBC setting Sponsor: Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Health Insurance | Insurance | Pfizer | Research | South Korea Health